A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment
Latest Information Update: 16 Feb 2023
At a glance
- Drugs Ganaxolone (Primary)
- Indications Partial epilepsies; Seizures
- Focus Registrational; Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 28 Apr 2017 Results of post-hoc analysis presented at the 69th Annual Meeting of the American Academy of Neurology
- 19 Jan 2017 This trial was discontinued in Bulgaria.
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.